UNIGE document Professional Article
previous document  unige:106806  next document
add to browser collection

Jusqu'où et jusqu'à quand traiter l'ostéoporose?

Published in Revue médicale suisse. 2017, vol. 13, no. 559, p. 859-862
Abstract Estrogen replacement therapy, selective modulators of the estrogen receptor (SERMs), bisphophonates and denosumab are antiresorptive therapies which can be used for several years. Teriparatide is still the only bone forming agent available, its use is limited to 24 months. Except the absence of new fragility fractures, there is no well defined target in the treatment of osteoporosis. Nevertheless persistence of high fracture risk (prevalent fractures and/or low BMD) on therapy indicates to maintain or intensify the treatment. On the contrary, if fracture risk is low, a « therapeutic window » could be considered after treatment with bisphosphonates, whereas after denosumab a short course of another treatment may be necessary.
Keywords Bone DensityBone Density Conservation Agents/administration & dosageEstrogen Replacement Therapy/methodsHumansOsteoporosis/complications/drug therapyOsteoporotic Fractures/prevention & controlSelective Estrogen Receptor Modulators/administration & dosageTeriparatide/administration & dosageTime Factors
PMID: 28727344
Full text
Article (Published version) (150 Kb) - public document Free access
Research group Génétique des ostéoporoses (544)
(ISO format)
UEBELHART, Brigitte Florence, FERRARI, Serge Livio. Jusqu'où et jusqu'à quand traiter l'ostéoporose?. In: Revue médicale suisse, 2017, vol. 13, n° 559, p. 859-862. https://archive-ouverte.unige.ch/unige:106806

234 hits



Deposited on : 2018-08-03

Export document
Format :
Citation style :